PURE Bioscience Reports First Quarter Results

SAN DIEGO, Calif., Dec. 18, 2007 – PURE Bioscience (OTCBB: PURE) today reported financial results for the first quarter ended October 31, 2007.  Revenues for the fiscal quarter were approximately $95,300 compared with revenues of $27,700 in the same quarter last year.  The Company reported a net loss of approximately $(1,008,700), or $(0.04) per share for the current quarter, compared with a loss of $(867,300), or $(0.04) per share in first fiscal quarter last year.

During the quarter, the Company raised more than $8 million in equity financing in a private placement of its securities.  Michael L. Krall, President and CEO of PURE Bioscience said, “We expect to file the registration statement for the previously announced private placement within the next 30 days; therefore, due to the required ‘quiet period,’ we are not at liberty to comment on results or future outlook at this time.”

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety.  Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds.  As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it.  PURE is headquartered in El Cajon, California (San Diego metropolitan area).  Additional information on PURE is available at www.purebio.com. 

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project,” "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.